CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-37
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $392.9M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 35.0¢ | $177.8K | 507.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 698196 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 47523 | 9 |
View Market Depth
| Last trade - 10.24am 27/06/2024 (20 minute delay) ? |
| OPT (ASX) Chart |